Patents by Inventor Guozhang Xu

Guozhang Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220389005
    Abstract: The present invention is directed to 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 8, 2022
    Inventors: Guozhang Xu, Tianbao Lu, Zhijie Liu, Micheal D. Gaul
  • Publication number: 20220315561
    Abstract: The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: October 6, 2022
    Inventors: Guozhang Xu, Tho V. Thieu, Zhijie Liu, Micheal D. Gaul
  • Publication number: 20220306632
    Abstract: The present invention is directed to bicyclic pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 29, 2022
    Inventors: Guozhang Xu, Zhijie Liu, Micheal D. Gaul
  • Publication number: 20220267298
    Abstract: The present invention is directed to quinazolin-4-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including the treatment of for example, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, End-stage kidney disease, kidney failure, etc.
    Type: Application
    Filed: July 29, 2020
    Publication date: August 25, 2022
    Inventors: Guozhang Xu, Micheal D. Gaul
  • Publication number: 20220242850
    Abstract: The present invention is directed to phthalazin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including the treatment of for example, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, End-stage kidney disease, kidney failure, etc.
    Type: Application
    Filed: June 29, 2020
    Publication date: August 4, 2022
    Inventors: Guozhang Xu, Micheal D. Gaul
  • Publication number: 20220220125
    Abstract: The present invention is directed to fused isoindolin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 14, 2022
    Inventor: Guozhang Xu
  • Publication number: 20220009906
    Abstract: The present invention is directed to isoindolin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including, but not limited to, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, end stage chronic kidney disease, kidney failure, etc.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 13, 2022
    Inventors: Guozhang Xu, Eugene B. Grant, Gee-Hong Kuo, Micheal D. Gaul
  • Publication number: 20210388015
    Abstract: The present invention is directed to glucopyranose derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.
    Type: Application
    Filed: October 24, 2019
    Publication date: December 16, 2021
    Inventor: Guozhang Xu
  • Publication number: 20210388016
    Abstract: The present invention is directed to glucopyranose derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.
    Type: Application
    Filed: October 24, 2019
    Publication date: December 16, 2021
    Inventor: Guozhang Xu
  • Patent number: 11098016
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 24, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Publication number: 20210238170
    Abstract: The present invention is directed to 5,5-difluoro- and 5-fluoro-5-methyl-C-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Application
    Filed: May 8, 2019
    Publication date: August 5, 2021
    Inventors: Guozhang Xu, Gee-Hong Kuo, Michael Gaul
  • Patent number: 11014917
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 25, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Publication number: 20200377462
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: August 12, 2020
    Publication date: December 3, 2020
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Patent number: 10815210
    Abstract: The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 27, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Yin Liang
  • Publication number: 20200291004
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Application
    Filed: June 2, 2020
    Publication date: September 17, 2020
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Patent number: 10774048
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: September 15, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Patent number: 10696662
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 30, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Publication number: 20190367469
    Abstract: The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.
    Type: Application
    Filed: November 8, 2017
    Publication date: December 5, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Yin Liang
  • Publication number: 20190218186
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: January 8, 2019
    Publication date: July 18, 2019
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Patent number: 10251864
    Abstract: The present invention is directed to indole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: April 9, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Micheal Gaul, Guozhang Xu, Bao-Ping Zhao